Product Data Sheet

Pelcitoclax

Cat. No.: HY-109185 CAS No.: 1619923-36-2

Molecular Formula: $C_{57}H_{66}ClF_{4}N_{6}O_{11}PS_{4}$

Molecular Weight: 1281.85

Target: Bcl-2 Family; Apoptosis


Pathway: **Apoptosis**

Storage: Powder -20°C 3 years

2 years

In solvent -80°C 6 months

> -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO: 200 mg/mL (156.02 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.7801 mL	3.9006 mL	7.8012 mL
	5 mM	0.1560 mL	0.7801 mL	1.5602 mL
	10 mM	0.0780 mL	0.3901 mL	0.7801 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (3.90 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (3.90 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	${\sf Pelcitoclax} \ ({\sf APG-1252}) \ is \ a \ potent \ {\sf Bcl-2/Bcl-xl} \ inhibitor \ with \ antineoplastic \ and \ pro-apoptotic \ effects^{[1]}.$
In Vitro	APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10 days) treatment inhibits xenograft tumor growth more obviously than the other groups ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c athymic nude mice (male, 4-6weeks) injected with N87 cells ^[1]	
Dosage:	25 mg/kg, 50 mg/kg, and 100 mg/kg	
Administration:	Intravenous injection; once a day; for 10 days	
Result:	Inhibited xenograft tumor growth more obviously than the other groups.	

REFERENCES

[1]. Hanjie Yi, et al. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com